Predictors of immediate bleeding during endoscopic submucosal dissection in gastric lesions.
BACKGROUND
Although there have been several reports regarding complications, especially immediate bleeding, of endoscopic mucosal resection for a gastric neoplasm, little is known about the predictors of complications of endoscopic submucosal dissection (ESD). Thus, this study was performed to evaluate the predictive factors for immediate bleeding during ESD procedures.


METHODS
We analyzed 167 patients with 167 gastric lesions from June 2006 to June 2007. Patient-related variables (age, gender, history of aspirin or anti-platelet agents, triple therapy for H. pylori, and use of a proton pump inhibitor), endoscopic variables (lesion size, location, type, and mucosal ulceration), procedure-related variables (procedure time and volume of submucosal injection), and the pathology diagnosis were evaluated as potential risk factors.


RESULTS
The mean age of the patients was 62 years. The mean size of the lesions was 15 mm. The overall en bloc resection rate was 98.2%. Immediate bleeding occurred in 20 out of 167 patients. Delayed bleeding was seen in only three patients within 24 h after the procedure. Older age and the location of the lesions (antrum) were associated with a lower frequency of bleeding (p = 0.006 and p = 0.007, respectively). On multivariate analysis, an older age (OR 0.931, 95% CI 0.88-0.98) and the location of the lesion (antrum; OR 0.254, 95% CI 0.09-0.69) were significant predictive factors for a successful ESD without bleeding.


CONCLUSIONS
The results of this study demonstrated that age and lesion location were related to the ESD procedure outcome.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University Hospital, 50 Samduk 2-Ga, Chung-gu, Daegu, 700-721, South Korea.
Seong Woo
SW
Jeon
Min Kyu
MK
Jung
Chang Min
CM
Cho
Won Young
WY
Tak
Young Oh
YO
Kweon
Sung Kook
SK
Kim
Yong Hwan
YH
Choi
D000367:Age Factors; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000706:statistics & numerical data; D002277:Carcinoma / Q000601:surgery*; D004210:Dissection; D004724:Endoscopy / Q000009:adverse effects*; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D005753:Gastric Mucosa; D006474:Hemorrhagic Disorders / Q000139:chemically induced; D016558:Hemostasis, Endoscopic; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D019106:Postoperative Hemorrhage / Q000453:epidemiology / Q000209:etiology; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011706:Pyloric Antrum / Q000601:surgery; D012307:Risk Factors; D013272:Stomach Diseases / Q000601:surgery*; D013274:Stomach Neoplasms / Q000601:surgery*
D000900:Anti-Bacterial Agents; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors